Piramal Pharma Limited (PPLPHARMA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Piramal Pharma Limited ₹121, price ₹198, upside -38.7%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Piramal Pharma Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 30, 2026.
How to read this chart
47‑month range ₹63.86 – ₹293.36 · fair‑value band ₹59.78 – ₹215.59 · the ₹197.97 price screens above the ₹121.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 30, 2026.
Follow Piramal Pharma in your weekly email
Every Wednesday you see whether Piramal Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network.
Show more
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Stock analysis
Piramal Pharma Limited (PPLPHARMA) currently trades at ₹197.97, while our model-based Fair Value estimate is ₹121.45, 38.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹90.69 per share, and 0 of the 11 models we run sit above the ₹197.97 price.
Bear case: the Asset-Based group reads lowest at ₹41.27, and 11 of the 11 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹59.78 (bear) to ₹215.59 (bull), the price of ₹197.97 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Piramal Pharma Limited reported revenue of ₹88.7B in FY2026 versus ₹64.7B in FY2022, a compound +8.2%/yr. Reported net income was −₹3.3B in FY2026.
Key figures
Market cap ₹262B (≈ $2.7B) · P/S ratio 3.01 · EPS (TTM) ₹−2.36 · Dividend yield 0.1% · Net margin −3.7% · Return on equity −4.0% · Return on assets (EBIT) 2.1% · Operating margin −1.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).
What moves the price
The share trades about 13% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −39%, PPLPHARMA screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹2.12 to ₹97.63). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹59.78Fair Value ₹121.45Bull ₹215.59
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.1%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.6% (2021) → 1.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+12.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +28.6% a year for the price and +8.3% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside−38.7% · Below median
Profitability
Return on assets0.4% · Below median
Net margin (TTM)−3.4% · Bottom 25%
Operating margin (TTM)−1.3% · Bottom 25%
Growth and dividend
Revenue growth17.4% · Above median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.53× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/S (TTM)0.03× · Cheapest 25%
P/FCF0.5× · Cheapest 25%
EV/EBITDA3.7× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)87· sector 24
PAST (return on equity)0· sector 28
HEALTH (low debt)74· sector 96
DIVIDEND (yield)1· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Piramal Pharma Limited (PPLPHARMA) overvalued or undervalued?
As of Sep 30, 2026, our model estimates a fair value of ₹121.45 versus a price of ₹197.97, about −39% upside (overvalued).
What is the fair value of PPLPHARMA?
Our model-based fair value for Piramal Pharma Limited is ₹121.45 (as of Sep 30, 2026), built from audited fundamentals. The current price: ₹197.97.
What is the quality score of PPLPHARMA?
Piramal Pharma Limited has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Piramal Pharma Limited (PPLPHARMA)?
Our model-based price target is the fair value of ₹121.45 (as of Sep 30, 2026) from 11 valuation models. Cautious scenario ₹59.78, optimistic scenario ₹215.59. It is a calculation from audited fundamentals, not an analyst target.
What is the Piramal Pharma Limited stock forecast for 2026?
Our models put fair value at ₹121.45, about −39% upside versus a price of ₹197.97 (overvalued). Cautious scenario ₹59.78, optimistic scenario ₹215.59. The calculation is refreshed regularly with new filings.
What is the revenue of Piramal Pharma Limited (PPLPHARMA)?
Piramal Pharma Limited reported trailing-twelve-month revenue of about ₹92.1B (latest available figure, as of Sep 30, 2026).
Does Piramal Pharma Limited pay a dividend?
Piramal Pharma Limited currently shows a dividend yield of about 0.07% relative to its recent price (as of Sep 30, 2026).
What growth is priced into Piramal Pharma Limited (PPLPHARMA)?
For today's price to be fair in a discounted-cash-flow model, Piramal Pharma Limited would have to grow free cash flow by +33.9 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +25.1 % per year. As of Sep 30, 2026.
What discount rate (WACC) does the fair value of PPLPHARMA use?
Our models discount Piramal Pharma Limited at 10.9 %: a base by market capitalisation (mid), damped by beta 0.34, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Piramal Pharma Limited that is +33.9 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Piramal Pharma Limited (PPLPHARMA) delivered so far?
Over the past 5 years revenue at Piramal Pharma Limited grew +25.1 % a year. The price currently implies +33.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Piramal Pharma Limited (PPLPHARMA) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into Piramal Pharma Limited (+33.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Piramal Pharma Limited (PPLPHARMA)?
The free-cash-flow yield on the price is 1.94 %: that much free cash flow Piramal Pharma Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Piramal Pharma Limited (PPLPHARMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Piramal Pharma Limited it is ₹121.45 per share (as of Sep 30, 2026), against a price of ₹197.97. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Piramal Pharma Limited stock overvalued or undervalued in 2026?
As of Sep 30, 2026, PPLPHARMA trades above its calculated fair value: price ₹197.97, fair value ₹121.45, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PPLPHARMA?
No. The price is what the market pays today (₹197.97); the fair value is what the company's own numbers justify (₹121.45). For Piramal Pharma Limited the two are ₹76.52 per share apart. That gap is exactly why we show both numbers side by side.
How much is Piramal Pharma Limited worth?
The market values Piramal Pharma Limited at about ₹262B (market capitalisation, as of Sep 30, 2026). Per share that is ₹197.97; our models calculate a fair value of ₹121.45 per share.
What do the bullish and bearish scenarios say about PPLPHARMA?
Our models span a range for Piramal Pharma Limited: cautious scenario ₹59.78, base ₹121.45, optimistic ₹215.59 per share (as of Sep 30, 2026, price ₹197.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Piramal Pharma Limited (PPLPHARMA)?
Balance-sheet figures for Piramal Pharma Limited (as of Sep 30, 2026): return on equity −4.0%, debt of 0.53 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is PPLPHARMA from its 52-week high?
Piramal Pharma Limited trades at ₹197.97, about 13% below its 52-week high of ₹226.62 and 49% above the low of ₹133.27 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹121.45 is for.
Which stocks are comparable to Piramal Pharma Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Piramal Pharma Limited stock attractive at the current price?
The data as of Sep 30, 2026: price ₹197.97, calculated fair value ₹121.45 (−39%), Quality Score 36/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PPLPHARMA calculated?
We run Piramal Pharma Limited through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹121.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Piramal Pharma Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Piramal Pharma Limited (PPLPHARMA)?
The closing price on Oct 1, 2026 was ₹197.97. Our model-based fair value is ₹121.45, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Piramal Pharma Limited right now?
Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (₹59.78 to ₹215.59). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Piramal Pharma Limited
How large is the market capitalisation of Piramal Pharma Limited (PPLPHARMA)?
The market capitalisation of Piramal Pharma Limited is ₹262B (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Piramal Pharma Limited (PPLPHARMA)?
The price-to-sales ratio of Piramal Pharma Limited is 3.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Piramal Pharma Limited (PPLPHARMA)?
Earnings per share at Piramal Pharma Limited are ₹−2.36. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Piramal Pharma Limited (PPLPHARMA)?
The dividend yield of Piramal Pharma Limited is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Piramal Pharma Limited (PPLPHARMA)?
The net margin of Piramal Pharma Limited is −3.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Piramal Pharma Limited (PPLPHARMA)?
The return on equity (ROE) of Piramal Pharma Limited is −4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Piramal Pharma Limited (PPLPHARMA)?
On an EBIT basis the return on assets of Piramal Pharma Limited is 2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Piramal Pharma Limited (PPLPHARMA)?
The operating margin of Piramal Pharma Limited is −1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Piramal Pharma Limited (PPLPHARMA)?
Revenue at Piramal Pharma Limited is growing +17.4% versus a year earlier (3y avg +8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Piramal Pharma Limited (PPLPHARMA)?
Earnings per share at Piramal Pharma Limited are growing +50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Piramal Pharma Limited (PPLPHARMA) carry?
The net debt of Piramal Pharma Limited is ₹44.5B (fiscal year 2026, ≈ 8.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Piramal Pharma Limited in the live analysis
One click puts Piramal Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
